Intriguingly, we observed a strong, statistically significant increase in the frequency of CD4+ IL-17/IL-10 double secreting cells in AML patients compared to HV (0.54 ± 0.63 and 0.075 ± 0.145% respectively; P = 0.002) (Figure 2c), whereas the percentage of IL-17 +/IFN-γ+ cells remained unchanged (P = 0.39) (Figure 2d). This evidence concerns the gene CD4 and acute myeloid leukemia.